Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 111B 400M 346M 323M 297M 558M 38.11B 567M 3.79B 1.49B 19.1B 1.5B 1.47B 63.15B P/E 2026 *
10.1x
P/E 2027 * 8.64x
Enterprise Value 111B 400M 346M 323M 297M 558M 38.11B 567M 3.79B 1.49B 19.1B 1.5B 1.47B 63.15B EV / Sales 2026 *
1.61x
EV / Sales 2027 * 1.49x
Free-Float
-
Yield 2026 *
5.27%
Yield 2027 * 5.96%
Aug. 02 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
Aug. 02 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
Jun. 08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
May. 31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
Apr. 30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
Apr. 27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
Apr. 06 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
Mar. 31 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
Mar. 26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-24 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day-1.23%
1 week+0.95%
Current month+0.95%
1 month-5.96%
3 months-4.30%
6 months-15.95%
Current year-10.48%
1 week 348
Extreme 348
356
1 month 337.5
Extreme 337.5
376.5
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 72 2020-04-01
Director/Board Member - 2018-12-04
Director/Board Member - 2020-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+0.95%-18.01%+341.54% 400M
-0.52%+3.21%+89.52%+127.32% 1,057B
+0.88%+1.13%+49.56%+49.69% 625B
+0.89%-1.95%+24.23%+64.44% 435B
+0.71%+3.87%+49.07%+37.85% 363B
+0.64%-0.49%+33.94%+40.01% 296B
+0.39%-5.83%+8.92%+7.85% 249B
+1.51%+6.69%+42.58%+57.57% 222B
+3.92%-0.46%-5.56%-52.32% 209B
+1.80%+2.30%+11.56%+66.35% 165B
Average +0.90%+0.74%+28.58%+74.03% 362.12B
Weighted average by Cap. +0.66%+1.22%+48.71%+64.66%

Financials

2026 *2027 *
Net sales 68.81B 248M 214M 200M 184M 346M 23.6B 351M 2.35B 922M 11.83B 931M 911M 39.1B 74.58B 269M 232M 217M 199M 375M 25.57B 380M 2.55B 1B 12.82B 1.01B 987M 42.38B
Net income 10.49B 37.8M 32.7M 30.53M 28.01M 52.68M 3.6B 53.52M 358M 141M 1.8B 142M 139M 5.96B 12.42B 44.75M 38.71M 36.15M 33.16M 62.38M 4.26B 63.37M 424M 166M 2.13B 168M 164M 7.06B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-08-07 PKR 348.95 -1.23% 205,576
26-08-06 PKR 353.28 +0.04% 136,230
26-08-05 PKR 353.14 +0.65% 142,976
26-08-04 PKR 350.87 +0.11% 90,776
26-08-03 PKR 350.50 +1.40% 137,467
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
348.95PKR
Average target price
510.00PKR
Spread / Average Target
+46.15%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock